These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38506229)

  • 1. Should we ignore SARS-CoV-2 disease?
    Nesteruk I
    Epidemiol Infect; 2024 Mar; 152():e57. PubMed ID: 38506229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends of the COVID-19 dynamics in 2022 and 2023 vs. the population age, testing and vaccination levels.
    Nesteruk I
    Front Big Data; 2023; 6():1355080. PubMed ID: 38269394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in managing COVID-19 from an emerging infectious disease to a common respiratory infectious disease: What are the subsequent impacts on and new challenges for healthcare systems?
    Karako K; Song P; Chen Y; Karako T
    Biosci Trends; 2022; 16(6):381-385. PubMed ID: 36567122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of lockdown on Covid-19 case fatality rate and viral mutations spread in 7 countries in Europe and North America.
    Pachetti M; Marini B; Giudici F; Benedetti F; Angeletti S; Ciccozzi M; Masciovecchio C; Ippodrino R; Zella D
    J Transl Med; 2020 Sep; 18(1):338. PubMed ID: 32878627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of SARS-CoV-2 mortality during the early stages of an epidemic: A modeling study in Hubei, China, and six regions in Europe.
    Hauser A; Counotte MJ; Margossian CC; Konstantinoudis G; Low N; Althaus CL; Riou J
    PLoS Med; 2020 Jul; 17(7):e1003189. PubMed ID: 32722715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Egypt's COVID-19 Recent Happenings and Perspectives: A Mini-Review.
    Saied AA; Metwally AA; Madkhali NAB; Haque S; Dhama K
    Front Public Health; 2021; 9():696082. PubMed ID: 34485226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.
    COVID-19 Cumulative Infection Collaborators
    Lancet; 2022 Jun; 399(10344):2351-2380. PubMed ID: 35405084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Universal screening for SARS-CoV-2 infection: a rapid review.
    Viswanathan M; Kahwati L; Jahn B; Giger K; Dobrescu AI; Hill C; Klerings I; Meixner J; Persad E; Teufer B; Gartlehner G
    Cochrane Database Syst Rev; 2020 Sep; 9(9):CD013718. PubMed ID: 33502003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Travel-related control measures to contain the COVID-19 pandemic: a rapid review.
    Burns J; Movsisyan A; Stratil JM; Coenen M; Emmert-Fees KM; Geffert K; Hoffmann S; Horstick O; Laxy M; Pfadenhauer LM; von Philipsborn P; Sell K; Voss S; Rehfuess E
    Cochrane Database Syst Rev; 2020 Oct; 10():CD013717. PubMed ID: 33502002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody tests for identification of current and past infection with SARS-CoV-2.
    Deeks JJ; Dinnes J; Takwoingi Y; Davenport C; Spijker R; Taylor-Phillips S; Adriano A; Beese S; Dretzke J; Ferrante di Ruffano L; Harris IM; Price MJ; Dittrich S; Emperador D; Hooft L; Leeflang MM; Van den Bruel A;
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013652. PubMed ID: 32584464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-pharmacological measures implemented in the setting of long-term care facilities to prevent SARS-CoV-2 infections and their consequences: a rapid review.
    Stratil JM; Biallas RL; Burns J; Arnold L; Geffert K; Kunzler AM; Monsef I; Stadelmaier J; Wabnitz K; Litwin T; Kreutz C; Boger AH; Lindner S; Verboom B; Voss S; Movsisyan A
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD015085. PubMed ID: 34523727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity in transmissibility and shedding SARS-CoV-2 via droplets and aerosols.
    Chen PZ; Bobrovitz N; Premji Z; Koopmans M; Fisman DN; Gu FX
    Elife; 2021 Apr; 10():. PubMed ID: 33861198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endemic characteristics of SARS-CoV-2 infection.
    Nesteruk I
    Sci Rep; 2023 Sep; 13(1):14841. PubMed ID: 37684338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-stratified analysis of SARS-CoV-2 infection and case fatality rate in China, Italy, and South Korea.
    Liu JQ; Xu JW; Sun CY; Wang JN; Wang XT; Chen X; Gao SL
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12575-12578. PubMed ID: 33336777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review.
    Nussbaumer-Streit B; Mayr V; Dobrescu AI; Chapman A; Persad E; Klerings I; Wagner G; Siebert U; Ledinger D; Zachariah C; Gartlehner G
    Cochrane Database Syst Rev; 2020 Sep; 9(9):CD013574. PubMed ID: 33959956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality Rates of Coronavirus Disease 2019 (COVID-19) Caused by the Novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2).
    Kandi V; Thungaturthi S; Vadakedath S; Gundu R; Mohapatra RK
    Cureus; 2021 Mar; 13(3):e14081. PubMed ID: 33903841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study.
    Laxminarayan R; B CM; G VT; Arjun Kumar KV; Wahl B; Lewnard JA
    Lancet Infect Dis; 2021 Dec; 21(12):1665-1676. PubMed ID: 34399090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis and comprehensive study of coronavirus outbreaks: SARS, MERS and COVID-19.
    Berber E; Sumbria D; Çanakoğlu N
    J Infect Public Health; 2021 Aug; 14(8):1051-1064. PubMed ID: 34174535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling of hypothetical SARS-CoV-2 point of care tests for routine testing in residential care homes: rapid cost-effectiveness analysis.
    Stevenson M; Metry A; Messenger M
    Health Technol Assess; 2021 Jun; 25(39):1-74. PubMed ID: 34142943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.